IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 55.15

Change

-1.18 (-2.09)%

Market Cap

N/A

Volume

0.69M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-2.92 (-2.16%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-1.32 (-2.08%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-2.59 (-2.69%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-1.08 (-1.43%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.04 (+0.21%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-3.90 (-4.14%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.37 (+1.40%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.37 (-1.47%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-0.39 (-0.73%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.53 (+3.19%)

USD 0.01B

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

+0.53 (+4.34%)

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

+0.53 (+4.34%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.35% 62% D 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.35% 62% D 52% F
Trailing 12 Months  
Capital Gain -5.61% 38% F 37% F
Dividend Return 0.96% 81% B- 19% F
Total Return -4.66% 38% F 31% F
Trailing 5 Years  
Capital Gain 31.84% 86% B+ 49% F
Dividend Return 7.27% 74% C 15% F
Total Return 39.10% 90% A- 41% F
Average Annual (5 Year Horizon)  
Capital Gain 4.66% 76% C+ 53% F
Dividend Return 5.66% 76% C+ 48% F
Total Return 1.00% 79% B- 24% F
Risk Return Profile  
Volatility (Standard Deviation) 17.63% 48% F 58% F
Risk Adjusted Return 32.10% 71% C- 48% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.